Clinical trials: Endometriosis
Endometriosis
Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis
This will be a randomized, double-blind, placebo-controlled, proof-of-mechanism phase 2 trial investigating the effect of quinagolide extended-release vaginal ring on reduction of lesions assessed by high-resolution magnetic…
- Trial name
- QLARITY (NCT03749109)
- Testing
- Quinagolide 1080 µg
- Where
- 11 sites in Denmark, Germany and 2 more
- Volunteers
- 67 people
- Sponsor
- Ferring Pharmaceuticals
Endometriosis
The EMPOWER Study: Endometriosis Diagnosis Using MicroRNA
Endometriosis is a complex, heterogeneous disease that may present inconsistently across women. Using disease-specific biomarkers and advanced biostatistics, DotLab is developing a biomarker test to confirm the presence of…
- Trial name
- EMPOWER (NCT04598698)
- Where
- 23 sites in United States
- Volunteers
- 750 people
- Sponsor
- Dot Laboratories, Inc.
Endometriosis
RNA Assays for Endometriosis Detection and Diagnosis
Endometriosis is a common disease that affects up to 10% of women of reproductive age. Diagnosis, however, is typically delayed (up to 12 years) and is usually made after surgery.
- Trial name
- RNA-EndoDx (NCT06907303)
- Testing
- EndoDx
- Where
- 2 sites in United States, South Africa
- Volunteers
- 400 people
- Sponsor
- Wren Laboratories LLC
Ovarian Cysts, Endometriosis
Evaluation of Adhexil Safety and Efficacy in Prevention and/or Reduction of Adhesions in Gynecological Surgery
The objective of this study is to evaluate the safety and efficacy of ADHEXIL™ in preventing and/or reducing post-operative adhesions in patients undergoing surgery involving the ovaries.
- Conditions
- Ovarian Cysts, Endometriosis, Adhesions
- Trial name
- NCT00865488
- Testing
- ADHEXIL
- Where
- 5 sites in United States, Germany and 3 more
- Volunteers
- 80 people
- Sponsor
- OMRIX Biopharmaceuticals
Endometriosis
Study to Investigate the Efficacy of a Non-hormonal Drug Against Endometriosis Associated Pelvic Pain
This study was designed as a proof-of-concept trial to evaluate safety, tolerability, and the efficacy of 1800 mg (ZK 811752 600 mg given orally three times daily) over 12 weeks for the treatment of endometriosis associated…
- Trial name
- NCT00185341
- Testing
- CCR1-Antagonist (BAY86-5047, ZK811752)
- Where
- 32 sites in Czechia, Denmark and 5 more
- Volunteers
- 110 people
- Sponsor
- Bayer
Endometriosis
A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
A randomized study evaluating the safety and efficacy of elagolix in the management of moderate to severe endometriosis-associated pain in adult premenopausal female subjects.
- Trial name
- ELARIS EM-II (NCT01931670)
- Testing
- Elagolix
- Volunteers
- 815 people
- Sponsor
- AbbVie
Endometriosis
A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain
The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe…
- Trial name
- ELENA (NCT05560646)
- Testing
- OG-6219
- Where
- 86 sites in United States, Belgium and 9 more
- Volunteers
- 354 people
- Sponsor
- Organon and Co
Endometriosis
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
The primary objective of this study is to assess the efficacy and safety of a range of oral doses of OBE2109 versus placebo, in reducing endometriosis associated pain.
- Trial name
- EDELWEISS (NCT02778399)
- Testing
- OBE2109
- Where
- 86 sites in United States, Poland and 2 more
- Volunteers
- 328 people
- Sponsor
- ObsEva SA
Endometriosis
A Study of HS-10518 in Healthy Female Participants
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HS-10518 in healthy adult premenopausal females in China.
- Trial name
- NCT06118827
- Testing
- HS-10518
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Endometriosis
Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)
The primary objective of this extension study is to assess the maintenance of efficacy of linzagolix administered orally once daily for up to an additional 6 months (for up to 12 months of treatment in total) in women who have…
- Trial name
- NCT04335591
- Testing
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg)
- Where
- 47 sites in United States, Austria and 7 more
- Volunteers
- 356 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Endometriosis, Moderate to Severe Endometriosis-associated Pain
Efficacy and Safety of BG2109 in Chinese Subjects With Endometriosis
The objective of this study is to demonstrate the efficacy and safety of BG2109 administered orally once daily at a dose of 100 mg alone or of 200 mg in combination with add-back hormone replacement therapy (ABT: estradiol (E2) 1…
- Trial name
- NCT05894135
- Testing
- BG2109 100mg, BG2109 200mg, ABT(E2 1 mg / NETA 0.5 mg)
- Where
- China
- Volunteers
- 540 people
- Sponsor
- Bio Genuine (Shanghai) Biotech Co., Ltd.